scholarly journals Effects of vitamin D supplementation on depression in patients with colorectal cancer

2020 ◽  
Author(s):  
JianWen Duan ◽  
YongSheng Chen ◽  
WenFei Wu ◽  
Cong Xiong ◽  
ZuLiang Hu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Vitamin D ◽  
Vitamin D3 ◽  
Rating Scale ◽  
Vitamin D Supplementation ◽  
Hydroxyvitamin D ◽  
Vitamin D3 Supplementation ◽  
Healthy Control ◽  
25 Hydroxyvitamin D ◽  
Vitamin D 3

Abstract Background: The relation and possible mechnism of vitamin D supplementation on depression in colorectal cancer (CRC) patients was not clearly ; Objective: This study investigates the effect of vitamin D supplementation on depression in colorectal cancer (CRC) patients. Methods : We recruited 168 CRC patients and 168 healthy control subjects into this study. 17-item Hamilton Depression Rating Scale (HDRS-17) was used to assess depression. Results: We found that 25-hydroxyvitamin D (25(OH)D) concentrations were independently associated with depression among CRC patients. For the 45 depressed patients receiving vitamin D3 supplementation, depression scores decreased markedly with 25(OH)D concentrations increasing to normal. Conclusion: Therefore, we advise monitoring this indicator in CRC patients and supplementing with vitamin D 3 when their 25(OH)D concentrations are low.

scholarly journals The efficacy of vitamin D3 supplementation in increasing 25-hydroxyvitamin D levels in childhood vitiligo patients receiving 308-nm-excimer light phototherapy

2019 ◽  
Author(s):  
Reiva Farah Dwiyana ◽  
Pramita K.C. Nugrahaini ◽  
D.P. Larasati ◽  
Inne Arline Diana ◽  
Reti Hindritiani ◽  
...  
Keyword(s):  
Vitamin D ◽  
Combination Therapy ◽  
Vitamin D3 ◽  
Vitamin D Supplementation ◽  
Oral Vitamin ◽  
Once Daily ◽  
Hydroxyvitamin D ◽  
Group I ◽  
Vitamin D3 Supplementation ◽  
25 Hydroxyvitamin D

Vitamin D deficiency is a condition often found in various autoimmune diseases, including vitiligo. There were clinical improvements in autoimmune patients who had been given oral vitamin D supplementation, as well as vitiligo patients. This study aimed to analyze the comparison effect of a combination therapy of 308-nmexcimer light phototherapy and vitamin D3 supplementation toward 308-nm-excimer light phototherapy alone to increase of serum 25-(OH)D levels in childhood vitiligo patients. Subjects consisted of 16 childhood vitiligo patients that divided into two groups; group I was given a combination of 308-nm-excimer light phototherapy and 5000 IU of vitamin D3 supplement once daily, while group II was given monotherapy of excimer light. There were highly significant increase of 25-(OH)D serum in both groups which were 324.00±119.066% and 29.84±36.106%, respectively. The very significant result was seen in a comparison of average increased of serum 25-(OH)D levels between both groups. The study concluded that combination of 308-nm-excimer light phototherapy and vitamin D3 supplementation gave a better effect than phototherapy only to increase of serum 25- (OH)D levels in childhood vitiligo patients.

Effects of Vitamin D Supplementation on Orthostatic Hypotension: Results from the STURDY Trial

2021 ◽  
Author(s):  
Stephen P Juraschek ◽  
Edgar R Miller 3rd ◽  
Amal A Wanigatunga ◽  
Jennifer A Schrack ◽  
Erin D Michos ◽  
...  
Keyword(s):  
Vitamin D ◽  
Orthostatic Hypotension ◽  
Vitamin D3 ◽  
Vitamin D Supplementation ◽  
Double Blind ◽  
Hydroxyvitamin D ◽  
Vitamin D Levels ◽  
Vitamin D3 Supplementation ◽  
25 Hydroxyvitamin D ◽  
Higher Doses

Abstract Background Vitamin D3 supplementation is considered a potential intervention to prevent orthostatic hypotension (OH) based on observational evidence that vitamin D levels are inversely associated with OH. Objectives With data from The Study to Understand Fall Reduction and Vitamin D in You (STURDY), a double-blind, randomized, response-adaptive trial, we determined if higher doses of vitamin D3 reduced risk of OH. Methods STURDY tested the effects of higher (1,000+ IU/day, i.e., 1,000, 2,000, and 4,000 IU/day combined) versus lower-dose vitamin D3 (200 IU/day, comparison) on fall risk in adults ages 70 years and older with low serum 25-hydroxyvitamin D (10-29 ng/mL). OH was determined at baseline, 3, 12, and 24 months by taking the difference between seated and standing blood pressure (BP). OH was defined as a drop in systolic or diastolic BP of at least 20 or 10 mmHg after 1 minute of standing. Participants were also asked about OH symptoms during the assessment and the preceding month. Results Among 688 participants (mean age 77 [SD, 5] years; 44% women; 18% Black), the mean baseline systolic/diastolic BP was 130 (19)/67 (11) mmHg, serum 25-hydroxyvitamin D was 22.1 (5.1) ng/mL, and 2.8% had OH. There were 2,136 OH assessments over the maximum 2-year follow-up period. Compared to 200 IU/day, 1,000+ IU/day was not associated with seated, standing, or orthostatic BP, and it did not lower risk of OH or orthostatic symptoms. Conclusions These findings do not support use of higher doses of vitamin D3 supplementation as an intervention to prevent OH.

Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD

2021 ◽  
Author(s):  
Cora M Best ◽  
Leila R Zelnick ◽  
Kenneth E Thummel ◽  
Simon Hsu ◽  
Christine Limonte ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D3 ◽  
Parent Compound ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Total Serum ◽  
P Value ◽  
Hydroxyvitamin D ◽  
Serum Vitamin D ◽  
Vitamin D3 Supplementation

Abstract Context The effect of daily vitamin D supplementation on the serum concentration of vitamin D (the parent compound) may offer insight into vitamin D disposition. Objective To assess the total serum vitamin D response to vitamin D3 supplementation and whether it varies according to participant characteristics. To compare results with corresponding results for total serum 25-hydroxyvitamin D (25(OH)D), which is used clinically and measured in supplementation trials. Design Exploratory study within a randomized trial. Intervention 2,000 International Units of vitamin D3 per day (or matching placebo). Setting Community-based. Participants 161 adults (mean ± SD age 70 ± 6 years; 66% males) with type 2 diabetes. Main Outcome Measures Changes in total serum vitamin D and total serum 25(OH)D concentrations from baseline to year 2. Results At baseline, there was a positive, nonlinear relation between total serum vitamin D and total serum 25(OH)D concentrations. Adjusted effects of supplementation were a 29.2 (95% CI: 24.3, 34.1) nmol/L increase in serum vitamin D and a 33.4 (95% CI: 27.7, 39.2) nmol/L increase in serum 25(OH)D. Among those with baseline 25(OH)D < 50 compared with ≥ 50 nmol/L, the serum vitamin D response to supplementation was attenuated (15.7 vs 31.2 nmol/L; interaction p-value = 0.02), whereas the serum 25(OH)D response was augmented (47.9 vs 30.7 nmol/L; interaction p-value = 0.05). Conclusions Vitamin D3 supplementation increases total serum vitamin D and 25(OH)D concentrations with variation according to baseline 25(OH)D, which suggests that 25-hydroxylation of vitamin D3 is more efficient when serum 25(OH)D concentration is low.

scholarly journals Effects of Genetic and Nongenetic Factors on Total and Bioavailable 25(OH)D Responses to Vitamin D Supplementation

2016 ◽  
Vol 102 (1) ◽  
pp. 100-110 ◽  
Author(s):  
Pang Yao ◽  
Liang Sun ◽  
Ling Lu ◽  
Hong Ding ◽  
Xiafei Chen ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Vitamin D3 ◽  
Controlled Trial ◽  
Vitamin D Supplementation ◽  
Inverse Association ◽  
Vitamin D Metabolism ◽  
Hydroxyvitamin D ◽  
Vitamin D3 Supplementation ◽  
Double Blinded

Abstract Context: Little is known about how genetic and nongenetic factors modify responses of vitamin D supplementation in nonwhite populations. Objective: To investigate factors modifying 25-hydroxyvitamin D [25(OH)D] and bioavailable 25(OH)D [25(OH)DBio] responses after vitamin D3 supplementation. Design, Setting, Participants, and Intervention: In this 20-week, randomized, double-blinded, placebo-controlled trial, 448 Chinese with vitamin D deficiency received 2000 IU/d vitamin D3 or placebo. Main Outcome Measures: Serum 25(OH)D, vitamin D-binding protein (VDBP), parathyroid hormone (PTH) and calcium were measured, and 25(OH)DBio was calculated based on VDBP levels. Six common polymorphisms in vitamin D metabolism genes were genotyped. Results: Between-arm net changes were +30.6 ± 1.7 nmol/L for 25(OH)D, +2.7 ± 0.2 nmol/L for 25(OH)DBio, and −5.2 ± 1.2 pg/mL for PTH, corresponding to 70% [95% confidence interval (CI), 62.8% to 77.2%] net reversion rate for vitamin D deficiency at week 20 (P < 0.001). Only 25(OH)DBio change was positively associated with calcium change (P < 0.001). Genetic factors (GC-rs4588/GC-rs7041, VDR-rs2228570, and CYP2R1-rs10741657; P ≤ 0.04) showed stronger influences on 25(OH)D or 25(OH)DBio responses than nongenetic factors, including baseline value, body mass index, and sex. An inverse association of PTH-25(OH)D was demonstrated only at 25(OH)D of <50.8 (95% CI, 43.6 to 59.0) nmol/L. Conclusions: Supplemented 2000 IU/d vitamin D3 raised 25(OH)D and 25(OH)DBio but was unable to correct deficiency in 25% of Chinese participants, which might be partially attributed to the effect of genetic modification. More studies are needed to elucidate appropriate vitamin D recommendations for Asians and the potential clinical implications of 25(OH)DBio.

Vitamin D in children with cystic fibrosis

2012 ◽  
Vol 97 (11) ◽  
pp. 982-984 ◽  
Author(s):  
Malcolm Brodlie ◽  
William A Orchard ◽  
Gordon A Reeks ◽  
Stewart Pattman ◽  
Helen McCabe ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Vitamin D ◽  
Vitamin D3 ◽  
Hydroxyvitamin D ◽  
Regional Centre ◽  
Vitamin D3 Supplementation ◽  
25 Hydroxyvitamin D

PurposeThe Cystic Fibrosis Trust in 2007 published a recommended target of 75-150 nmol/L for 25-hydroxyvitamin D (25-OHD). In 2008 we found that only 10% of pancreatic insufficient (PI) children met this target. An increase in supplementation was implemented and a repeat audit performed in 2010.MethodsPI children ≥1 year under sole-care in our regional centre were included. Vitamin D3 supplementation increased by >450% to either 3800 IU/day liquid or 800 IU daily plus 20,000 IU weekly tablets. In 2010 pancreatic sufficient (PS) children were also audited separately.ResultsThe median 25-OHD level increased from 51.5 nmol/L in 2008 (n=78, 10% >75 nmol/L) to 72 nmol/L in 2010 (n=72, 51% >75 nmol/L), p<0.0001. In PS children (n=15 in 2010) 87% had 25-OHD levels <75 nmol/L.ConclusionsA substantial increase in supplementation led to a significant increase in 25-OHD levels but around half still failed to reach the recommended target.

scholarly journals Effect of daily 2000 IU versus 800 IU vitamin D on blood pressure among adults age 60 years and older: a randomized clinical trial

2020 ◽  
Vol 112 (3) ◽  
pp. 527-537
Author(s):  
Lauren A Abderhalden ◽  
Sandra Meyer ◽  
Bess Dawson-Hughes ◽  
E John Orav ◽  
Ursina Meyer ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Vitamin D ◽  
Knee Osteoarthritis ◽  
Vitamin D3 ◽  
Vitamin D Supplementation ◽  
Control Group ◽  
High Dose ◽  
Hydroxyvitamin D ◽  
Daily Vitamin ◽  
25 Hydroxyvitamin D

ABSTRACT Background Observational studies report higher blood pressure (BP) among individuals with lower 25-hydroxyvitamin D concentration. Whether dosage of vitamin D supplementation has a differential effect on BP control remains unclear. Objective The study aimed to determine if daily vitamin D supplementation with 2000 IU is more effective than 800 IU for BP control among older adults. Methods This randomized, double-blind, ancillary trial of the Zurich Multiple Endpoint Vitamin D Trial in Knee Osteoarthritis enrolled adults aged ≥60 y who underwent elective surgery due to severe knee osteoarthritis. Participants were randomly assigned to receive high dose (2000 IU) or standard dose (800 IU) daily vitamin D3 for 24 mo. Outcomes included daytime and 24-h mean systolic BP. BP variability and serum 25-hydroxyvitamin D concentration were examined in a post hoc and observational analysis. Results Of the 273 participants randomly assigned, 250 participants completed a follow-up 24-h ambulatory BP monitoring (mean age: 70.4 ± 6.4 y; 47.2% men). The difference in daytime mean systolic BP reduction between the 2000 IU (n = 123) and 800 IU (n = 127) groups was not statistically significant (−2.75 mm Hg vs. −3.94 mm Hg; difference: 1.18 mm Hg; 95% CI: −0.68, 3.05; P = 0.21), consistent with 24-h mean systolic BP. However, systolic BP variability was significantly reduced with 2000 IU (average real variability: −0.37 mm Hg) compared to 800 IU vitamin D3 (0.11 mm Hg; difference: −0.48 mm Hg; 95% CI: −0.94, −0.01; P = 0.045). Independent of group allocation, maximal reductions in mean BP were observed at 28.7 ng/mL of achieved serum 25-hydroxyvitamin D concentrations. Conclusions While daily 2000 IU and 800 IU vitamin D3 reduced mean systolic BP over 2 y to a small and similar extent, 2000 IU reduced mean systolic BP variability significantly more compared with 800 IU. However, without a placebo control group we cannot ascertain whether vitamin D supplementation effectively reduces BP. This trial was registered at www.clinicaltrials.gov as NCT00599807.

A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections

2009 ◽  
Vol 137 (10) ◽  
pp. 1396-1404 ◽  
Author(s):  
M. LI-NG ◽  
J. F. ALOIA ◽  
S. POLLACK ◽  
B. A. CUNHA ◽  
M. MIKHAIL ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D3 ◽  
Respiratory Tract Infections ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Hydroxyvitamin D ◽  
Vitamin D3 Supplementation ◽  
25 Hydroxyvitamin D ◽  
Upper Respiratory ◽  
Tract Infections

SUMMARYVitamin D has been shown to be an important immune system regulator. Vitamin D insufficiency during winter may cause increased susceptibility to upper respiratory tract infections (URIs). To determine whether vitamin D supplementation during the winter season prevents or decreases URI symptoms, 162 adults were randomized to receive 50 μg vitamin D3 (2000 IU) daily or matching placebo for 12 weeks. A bi-weekly questionnaire was used to record the incidence and severity of URI symptoms. There was no difference in the incidence of URIs between the vitamin D and placebo groups (48 URIs vs. 50 URIs, respectively, P=0·57). There was no difference in the duration or severity of URI symptoms between the vitamin D and placebo groups [5·4±4·8 days vs. 5·3±3·1 days, respectively, P=0·86 (95% CI for the difference in duration −1·8 to 2·1)]. The mean 25-hydroxyvitamin D level at baseline was similar in both groups (64·3±25·4 nmol/l in the vitamin D group; 63·0±25·8 nmol/l in the placebo group; n.s.). After 12 weeks, 25-hydroxyvitamin D levels increased significantly to 88·5±23·2 nmol/l in the vitamin D group, whereas there was no change in vitamin D levels in the placebo group. There was no benefit of vitamin D3 supplementation in decreasing the incidence or severity of symptomatic URIs during winter. Further studies are needed to determine the role of vitamin D in infection.

Sign in / Sign up

Export Citation Format

Share Document